Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Balingen – page 25

689 clinical trials in Balingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Balingen at a glance
689
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

689 trials in Balingen

Open in trial search

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Lichen planus

Not yet recruiting

Efficacy and safety of GIA632 versus placebo in adults with moderate to severe cutaneous lichen planus

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GIA632
  • Sponsor:Novartis Pharma AG

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Angina pectoris

Not yet recruiting

Study of Sublingual Glyceryl Trinitrate Spray to Reduce Angina in Adults with Symptomatic Coronary Artery Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glyceryl Trinitrate
  • Sponsor:G. Pohl-Boskamp GmbH & Co. KG

Avian influenza

Not yet recruiting

Immunogenicity and safety of intradermal zoonotic influenza vaccine (H5N8) compared with intramuscular administration in adults 40–80 years with avian influenza

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:INFLUENZA A/ASTRAKHAN/3212/2020 (H5N8)-LIKE STRAIN (CBER-RG8A) (CLADE 2.3.4.4B)
  • Sponsor:University Of Antwerp

Multifocal motor neuropathy

Not yet recruiting

Phase 1b study of empasiprubart in adults with multifocal motor neuropathy to assess nerve morphology by ultrasound

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Hereditary ataxia+1

Not yet recruiting

Long‑term safety of intrathecal VO659 in participants with Huntington’s disease, spinocerebellar ataxia type 1 or type 3

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:VO659
  • Sponsor:Vico Therapeutics B.V.

Non-small cell lung cancer

Not yet recruiting

Pembrolizumab alone versus pembrolizumab with chemotherapy drug combination in women with advanced non‑small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Retinal dystrophy

Not yet recruiting

A Study of ATSN-201 Gene Therapy for Patients with X-linked Retinoschisis (RS1-associated) to Assess Safety and Visual Function

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ziloretgene parvec
  • Sponsor:Atsena Therapeutics Inc.

Ischaemic stroke

Not yet recruiting

Enhanced dual antiplatelet therapy with clopidogrel and acetylsalicylic acid for secondary prevention in patients with mild ischemic stroke

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Technische Universitat Dresden

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK5733584
  • Sponsor:Glaxosmithkline Research & Development Limited

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.